Robert Plenge

Robert Plenge

Chief Tech/Sci/R&D Officer at BRISTOL-MYERS SQUIBB COMPANY

Net worth: 2 M $ as of 2026-08-30

55 year
Health Technology
Consumer Services
Health Services

Profile

Dr. Robert M.
Plenge
is an Independent Director at BioMarin Pharmaceutical, Inc. and a Chief Research Officer, EVP & Head-Research at Bristol Myers Squibb Co. He is on the Board of Directors at BioMarin Pharmaceutical, Inc. and PhRMA Foundation.
Dr. Plenge was previously employed as a VP-Translational Development & Research by Celgene Corp., a Vice President & Head-Translational Medicine by Merck & Co., Inc., an Associate Member-Broad Institute by The Brigham & Women's Hospital, Inc., and an Associate Member by The Broad Institute, Inc. He also served on the board at Translate Bio, Inc. He received his undergraduate degree from the University of California San Diego and a doctorate degree from Case Western Reserve University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-03-09 24,754 ( 0% ) 2 M $ 2026-08-30
2026-09-09 6,140 ( 0% ) 400 512 $ 2026-08-30

Robert Plenge active positions

CompaniesPositionStart
BRISTOL-MYERS SQUIBB COMPANY Chief Tech/Sci/R&D Officer 2019-10-31
BIOMARIN PHARMACEUTICAL INC. Director/Board Member 2026-09-09
Director/Board Member -
Director/Board Member -

Former positions of Robert Plenge

CompaniesPositionEnd
TRANSLATE BIO, INC. Director/Board Member 2021-09-13
MERCK & CO., INC. Corporate Officer/Principal 2017-04-30
Corporate Officer/Principal 2012-12-31
Corporate Officer/Principal 2012-12-31
CELGENE Chief Tech/Sci/R&D Officer -
See the detail of Robert Plenge's experience

Training of Robert Plenge

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

88

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Technology

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!